Esperion Therapeutics (ESPR) Current Assets (2012 - 2026)

Esperion Therapeutics has reported Current Assets for 15 years, with the latest figure at $459.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 44.13% year-over-year to $459.5 million; the trailing twelve-month figure through Mar 2026 stood at $459.5 million (up 44.13% YoY), and the FY2025 full-year result was $462.6 million, up 36.86% from the prior year.
• Current Assets for Q1 2026 stood at $459.5 million, down from $462.6 million in the prior quarter.
• The five-year high for Current Assets was $462.6 million in Q4 2025, with the low at $201.1 million in Q4 2023.
• Historically, Current Assets has averaged $309.1 million across 5 years, with a median of $307.6 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets dropped 25.01% — and 2024, when it surged 68.1%.
• Esperion Therapeutics' Current Assets stood at $246.7 million in 2022, then fell by 18.49% to $201.1 million in 2023, then surged by 68.1% to $338.0 million in 2024, then surged by 36.86% to $462.6 million in 2025, then dropped by 0.67% to $459.5 million in 2026.
• The last three Current Assets figures came in at $459.5 million (Q1 2026), $462.6 million (Q4 2025), and $360.5 million (Q3 2025), per Business Quant data.